Hair Loss Treatments for Women and Men Are Getting an Overdue Upgrade Thanks to New Drug Pipeline
Pattern hair loss touches tens of millions of Americans, yet for nearly three decades the prescription options barely changed. Minoxidil arrived in 1988. Finasteride followed in 1997. Women, largely excluded from trials built around male hormones, were left with topical minoxidil and limited alternatives. That’s finally shifting.
Three drugs now in late-stage clinical development are targeting androgenetic alopecia through entirely new mechanisms, and two of them were built with women in mind from day one. Here’s what each one does, where it stands and what you can actually do right now.
What Makes These New Hair Loss Drugs Different From Minoxidil and Finasteride
The two existing FDA-approved treatments work through blunt mechanisms. Minoxidil improves blood flow to follicles and must be used indefinitely to maintain results. Finasteride blocks DHT production throughout the body, which is why its hormonal effects make it largely unsuitable for women of reproductive age.
The three drugs now moving through trials take more targeted approaches: blocking DHT only at the follicle, waking up dormant stem cells at the cellular level, or delivering oral minoxidil through an extended-release formula designed to reduce cardiovascular risk.
VDPHL01: The Oral Hair Loss Pill Designed for Men and Women
Veradermics’ VDPHL01 is an extended-release oral minoxidil tablet engineered to deliver hair regrowth benefits while avoiding the heart-related risks tied to immediate-release oral minoxidil. It’s non-hormonal, making it a candidate for both sexes. Phase 2/3 Study 302 topline results released April 27, 2026 met all primary and key secondary endpoints, with robust hair growth seen in both once-daily and twice-daily dosing arms.
A second Phase 3 trial in men (Study 304) is expected to report data in the second half of 2026. A dedicated Phase 3 trial in women (Study 306) is actively recruiting. Veradermics is targeting an NDA submission in early 2027, with estimated market availability in late 2027 to early 2028.
Clascoterone 5%: A Topical Blocker That Doesn’t Enter the Bloodstream
Cosmo Pharmaceuticals’ clascoterone 5% works by blocking DHT directly at the androgen receptor inside the follicle, with no systemic absorption. That’s the critical distinction from finasteride: because it stays local, researchers believe it may be appropriate for women with androgenetic alopecia.
The Phase 3 SCALP 1 and SCALP 2 trials enrolled 1,465 men across the United States and Europe, the largest Phase 3 program ever run for a topical AGA treatment. A December 2025 press release from Cosmo Pharmaceuticals reported that SCALP 1 showed a 539 percent relative improvement in target-area hair count versus placebo and SCALP 2 showed 168 percent, with a favorable safety profile across both studies.
Regulatory submissions are underway in the US and Europe following 12-month safety follow-up completion in spring 2026.
PP405: A Stem Cell Approach to Regrowing Hair
Pelage Pharmaceuticals’ PP405 targets hair loss at a level neither of the above drugs reaches: the dormant stem cells inside follicles that have stopped cycling. Rather than slowing loss or blocking hormones, it’s designed to restart growth at the cellular level. The Phase 2a trial enrolled 78 men and women across diverse skin and hair types.
Four weeks of dosing followed by eight weeks of observation found no systemic absorption and a significant clinical response in men with higher-degree hair loss by week 8. The trial included women from the outset. Phase 3 trials are planned for 2026, though consumer excitement is running ahead of the clinical data at this stage.
When These Hair Loss Treatments Could Actually Reach Patients
The realistic timeline for any of these reaching pharmacy shelves starts in late 2027 at the earliest. VDPHL01 has the most advanced data package and the clearest NDA submission timeline.
Clascoterone is completing its safety dataset with regulatory submissions already in motion. PP405 is the earliest in development of the three, with Phase 3 still ahead. None of these are available outside of clinical trials now, and timelines shift based on trial outcomes and regulatory review.
What Dermatologists Recommend For Hair Loss While You Wait
Topical minoxidil remains the most clinically supported option currently available for both men and women, and a dermatologist can evaluate whether off-label oral minoxidil is appropriate for individual patients. Low-level laser therapy works through a completely different mechanism than any drug in the pipeline and can be added on top of existing treatment.
A 2026 12-month prospective trial in Dermatologic Therapy found sustained improvements in hair density over a full year for androgenetic alopecia, with additive effects noted when laser therapy was combined with minoxidil. At-home FDA-cleared devices make that a practical daily option without clinic visits, and represent one of the most evidence-backed things you can do right now while the next generation of hair loss treatments moves toward approval.
This article was created by content specialists using various tools, including AI.
